Anti-cancer and wound healing compounds

Details Anti-cancer and wound healing compounds Anti-cancer and wound healing compounds

2006-07-04

2006-07-04

Tate, Christopher R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07071164

ABSTRACT:
The invention provides inhibitors of matrix metalloproteinases that are useful as anti-tumor agents and for treating wounds. The inhibitors are peptides having sequences related to cleavage regions of the proenzyme forms of matrix metalloproteinases. The peptide inhibitors of the invention can be formulated into therapeutic compositions, lotions, creams, skin covering and wound dressings that inhibit expression of vascular endothelial growth factor and encourage healing.

REFERENCES:
patent: 4424552 (1984-01-01), Saint Marcoux
patent: 5270447 (1993-12-01), Liotta et al.
patent: 5280106 (1994-01-01), Liotta et al.
patent: 5372809 (1994-12-01), Liotta et al.
patent: 5585356 (1996-12-01), Liotta et al.
patent: 5698671 (1997-12-01), Stetler-Stevenson et al.
patent: 5770691 (1998-06-01), Fields et al.
patent: 5811252 (1998-09-01), Verheijen
patent: 5869277 (1999-02-01), Stetler-Stevenson et al.
patent: 6043087 (2000-03-01), Bini et al.
patent: 6127139 (2000-10-01), Te Koppele et al.
patent: 6184022 (2001-02-01), Seiki et al.
patent: 6191225 (2001-02-01), Barkac et al.
patent: 6204043 (2001-03-01), Shapiro
patent: H1973 (2001-07-01), Hu
patent: 6274703 (2001-08-01), Goldberg
patent: 6399371 (2002-06-01), Falduto et al.
patent: 6482802 (2002-11-01), Hu et al.
patent: 6753310 (2004-06-01), Oku et al.
patent: 6812339 (2004-11-01), Venter et al.
patent: 6906036 (2005-06-01), Quirk et al.
patent: 2001/0016333 (2001-08-01), Seiki et al.
patent: 2001/0031478 (2001-10-01), Bronstein et al.
patent: 2002/0099004 (2002-07-01), Lund et al.
patent: 2003/0012794 (2003-01-01), Srivastava et al.
patent: 2003/0096757 (2003-05-01), Quirk et al.
patent: 2003/0166567 (2003-09-01), Quirk et al.
patent: 2003/0199440 (2003-10-01), Dack et al.
patent: 2004/0010001 (2004-01-01), Au et al.
patent: 2004/0259802 (2004-12-01), Yang et al.
patent: 0917165 (1999-05-01), None
patent: 06213888 (1994-05-01), None
patent: 06300757 (1994-10-01), None
patent: 07159402 (1995-06-01), None
patent: 07330795 (1995-12-01), None
patent: 08134098 (1996-05-01), None
patent: 08136548 (1996-05-01), None
patent: 08217800 (1996-08-01), None
patent: 09023889 (1997-01-01), None
patent: 09084589 (1997-03-01), None
patent: 09087299 (1997-03-01), None
patent: 09136841 (1997-05-01), None
patent: 09206099 (1997-08-01), None
patent: 10210982 (1998-08-01), None
patent: 10287700 (1998-10-01), None
patent: 10313896 (1998-12-01), None
patent: 2000270874 (2000-10-01), None
patent: 2001011093 (2001-01-01), None
patent: 2001072589 (2001-03-01), None
patent: WO-WO 90/10228 (1990-09-01), None
patent: WO-WO 94/10208 (1994-05-01), None
patent: WO-9502045 (1995-01-01), None
patent: WO-WO 96/18725 (1997-06-01), None
patent: WO-WO 97/25437 (1997-07-01), None
patent: WO-WO 98/04287 (1998-02-01), None
patent: WO-WO 98/12309 (1998-03-01), None
patent: WO-WO 98/31818 (1998-07-01), None
patent: WO-9834641 (1998-08-01), None
patent: WO-WO 98/40475 (1998-09-01), None
patent: WO-WO 98/42865 (1998-10-01), None
patent: WO-WO 99/05261 (1999-02-01), None
patent: WO-99/31969 (1999-07-01), None
patent: WO-9958126 (1999-11-01), None
patent: WO-WO 00/20860 (2000-04-01), None
patent: WO-0053219 (2000-09-01), None
patent: WO-0074634 (2000-12-01), None
patent: WO-WO 01/10437 (2001-02-01), None
patent: WO-0113937 (2001-03-01), None
patent: WO-WO 01/38558 (2001-05-01), None
patent: WO-0154723 (2001-08-01), None
patent: WO-WO 01/62206 (2001-08-01), None
patent: WO-WO 01/62261 (2001-08-01), None
patent: WO-WO 00/63227 (2001-10-01), None
patent: WO-03018748 (2003-03-01), None
Agren, Magnus S., “Matrix metalloproteinases (MMPs) are required for re-epitheliazation..”,arch Dermatol Res, (1999), 291: 583-590.
Attie, Kenneth M., “Genetic studies in idiopathic short stature”,Current Opinion in Pediatrics, (2000), 12:400-404.
Azzam, HS , et al., “Association of MMP-2 activation potential with metastic . . . ”,1: J Natl Cancer Inst, (1993), (21):1758-64.
Baker, EA , et al., “Proteinases, their inhibitors, and cytokine profiles in acute wound fluid.”,1: Wound Repair Regen, (2000), (5):392-8.
Becker, Joseph W., et al., “Stromelysin-1: Three-dimensional structure of the inhibited . . . ”,7-Enzymes vol. 123, (1995), 415.
Becker, Joseph W., et al., “Stromelysin-1: Three-dimensional structure of the inhibited . . . ”,Protein Science, (1995), 4:1966-1976.
Bhide, VM , et al., “Use of a fluorogenic septapeptide matrix metalloproteinase assay . . . ”,1: J Periodontol May 2000:71(5):690-700, (2000), 690-700.
Bickett, DM , et al., “A high Throughout fluorogenic substrate for interstital collagenase . . . ”,1: Anal Biochem, (1993), (1):58-64.
Bickett, DM , et al., “A high throughput fluorogenic substrate for stromelysin (MMP-2).”,1: Ann N Y Acad Sci, (1994), 732:351-5.
Blaschke, Rudiger J., et al., “SHOX: Growth, Leri-Weill and Turner Syndromes”,TEM vol. 11, (2000), 227-230.
Bremer, C , et al., “In Vivo molecular toarget assessment or matrix metaloproteinase . . . ”,1: Nat Med, (2001), (6):743-8.
Brown, Peter D., “Cellular activation of the 72 kda type IV pro collagenase/TIMP-2 complex”,13-Mammalion Biochem. vol. 119., (1993), 573.
Brown, PD , et al., “Cellular activation of the 72 kDa type IV procollagenase/TIMP-2 . . . ”,1: Kidney Int, (1993), (1):163-70.
Brown, Rebeccah L., et al. “PDGF and TGF-a Act Synergistically to Improve Wound Healing . . . ”,Journal of Surgical Research 56, (1994), 562-570.
Browner, Michelle F., et al., “Matrilysin-Inhibitor Complexes: Common Themes among Metalloproteases”,Biochemistry, (1995), 34, 6602-6610.
Cabrele, Chiara , et al., “Y-receptor affinity modulation by the design of pancreatic..”,Peptides 22, (2001), 365-378.
Calabrese, Edward J., “Cell Migration / Chemotaxis: Biphasic Dose Responses”,Critical Reviews in Toxicology, 31(4&5), (2001), 615-624.
Calvin, Melissa , “Cutaneous Wound Repair”,Wounds: A Compendium of Clinical Research and Practice vol. 10 No. 1, (1998), 12-32.
Chen, LC , et al., “Disruption of the cysteine-75 and zinc ion coordination is not sufficient . . . ”,1: Biochemistry, (1993),(39):10289-95.
Chin, Jason W., et al., “Concerted Evolution of Structureand Function in a Miniature Protein . . . ”,J. Am. Chem. Soc., (2001), 2929-2930.
Chin, Jason W., et al., “Methodology for Optimizing Functional Miniature Proteins Based on Avian . . . ”,Bioorganic, (2001),(2001) 1501-1505.
Clark, Richard A., “Wound Repair”,The Molecular and Cellular Bilogy of Wound Repair—2nd ed., (1996), 3-50.
Colandrea, Teresa D., et al., “Epidermal Expression of Collagenase Delays Wound-Healing . . . ”,The Society of Investigative Dermatology, (1998), 1029-1033.
Duivenoorden, Wilhelmina C., et al., “Use of Tetracycline as an Inhiitor of Matrix Metalloproteinase . . . ”,Invasion Metastasis, (1997), 312-322.
Duncan, ME , et al., “Human matrix metalloproteinase-9: activation by limited trypsin”,1:Eur J Biochem Nov. 15, 1998.
Farmer, WH , et al., “A continuous fluorescent assay for measuring protease activity . . . ”,1: Anal Biochem, (1991), (2):347-52.
Fernandez-Catalan, Carlos , et al., “Crystal structure of the complex formed by the membrane type . . . ”,The EMBO Journal, (1998), vol. 17 No. 17 (5238-5248).
Freije, JM , “Molecular cloning and expression of collagenase-3, a novel . . . ”,1: J Biol Chem, (1994), (24):16766-73.
Freire, E , et al., “Calorimentrically Determined Dynamics Of Complex Unfolding . . . ”,Biophys. Chem., (1990), 19:159-88.
Garbett, EA , et al., “Proteolysis in human breast and colorectal cancer.”,1: Br J Cancer, (1999), (2):287-93.
Gomis-Ruth, Franz-Xaver , et al., “Mechanism of inhibition of the human matrix metalloproteinase . . . ”,Nature vol. 389, (1997), 77-81.
Grams, Frank , et al., “X-ray structures of h

Affiliated with

Also associated with

Rating

Anti-cancer and wound healing compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-cancer and wound healing compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer and wound healing compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3572233